GISSI

From Wikipedia, the free encyclopedia

This article may not meet the general notability guideline or one of the following specific guidelines for inclusion on Wikipedia: Biographies, Books, Companies, Fiction, Music, Neologisms, Numbers, Web content, or several proposals for new guidelines. If you are familiar with the subject matter, please expand or rewrite the article to establish its notability. The best way to address this concern is to reference published, third-party sources about the subject. If notability cannot be established, the article is more likely to be considered for redirection, merge or ultimately deletion, per Wikipedia:Guide to deletion.
This article has been tagged since November 2007.

The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) (Italian group for the study of the survival of Myocardial Infarction) is an influential cardiology research group founded as a collaboration between two Italian organisations – the Mario Negri Institute and the Associazione Nazionale dei Medici Cardiologi Ospedalieri (ANMCO).[1] The trials carried out by GISSI have "obtained wide recognition in the international world of cardiology and are considered a methodological landmark"[1]. Four large-scale clinical trials over the past 20 years (GISSI 1[2][3], GISSI 2[4][5], GISSI 3[6], GISSI Prevention[7]) have involved more than 60,000 patients with acute myocardial infarction (AMI).[1]

[edit] References

  1. ^ a b c GISSI > Presentation > Presentation
  2. ^ "Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)" (1986). Lancet 1 (8478): 397–402. PMID 2868337. 
  3. ^ "Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI)" (1987). Lancet 2 (8564): 871–4. PMID 2889079. 
  4. ^ "GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico" (1990). Lancet 336 (8707): 65–71. PMID 1975321. 
  5. ^ "In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group" (1990). Lancet 336 (8707): 71–5. PMID 1975322. 
  6. ^ "GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico" (1994). Lancet 343 (8906): 1115–22. PMID 7910229. 
  7. ^ "Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico" (1999). Lancet 354 (9177): 447–55. PMID 10465168. 

[edit] Further reading

 This article about a medical organization or association is a stub. You can help Wikipedia by expanding it.